Letter of Intent due: July 21, 2017, 11:59 PM ET
If LOI is accepted, APPLICATION is due: September 25, 2017, 11:59 PM ET
The Epilepsy Innovation Seal of Excellence awards are, like New Therapy Commercialization Grants (NTCG), designed to accelerate the advancement of research from the laboratory to the patient. SEALs are provided to academic and commercial groups worldwide. The program seeks to advance the development of new therapies including but not limited to medicines, biologics or devices. All proposals must demonstrate a clear path from the lab to the patient and are evaluated with consideration for their potential value to patients, likelihood of successful development including regulatory approval and the timeframe of development. Drug development may be stimulated at the early phases leading to an IND.
The Epilepsy Innovation Seal of Excellence award is not primarily a grant program. The program provides a competitive, in-depth review by the Scientific and Business Advisory Boards and an actual SEAL that may be used by the awardee to generate interest in the project. The applicants will typically have a research budget of between $1 and $5M for the overall project--amounts that currently exceed the resources of the Epilepsy Foundation. The Epilepsy Foundation will assist the awardees in finding funds for the selected projects.
Epilepsy Innovation Seal of Excellence Award
Applicants must demonstrate background work beyond the basic science discovery stage. Applications are accepted for a wide range of products; projects in drug development must be at least pre-IND, with outstanding promise, usually from animal models.
Areas of interest include:
Novel approaches to treatment.
Platform technology to advance screening techniques that can be utilized by multiple laboratories, including utility of techniques for early proof-of-concept trials.
Adaptation of treatment in development for another therapeutic area to assess utility for epilepsy (while maintaining patent protection).
All proposals will be evaluated by our Business and Scientific Advisory Boards, as described below:
Proposals are rated on the likelihood of success by the Business Advisory Board as:
Intellectual Property Strategy & Status; Freedom To Operate
Can this Get to Patients: Investment Potential & Likelihood of Ongoing Funding Support
Probability of Success / Time Factor
Fit with Program Mission / Patient Impact
Proposals are rated on the likelihood of success by the Scientific Advisory Board as:
Quality of Science
Probability of Successful completion of milestones / outlined program
Timeframe of Success
Fit with Program Mission / Impact on Patients
These grants are awarded primarily to programs that have progressed beyond the basic science discovery stage. Programs that seek to develop potential drugs should have identified at least one lead compound, which may be at the pre-IND stage, in order to be competitive for a New Therapy Commercialization Grant. Investigators of drugs are strongly advised to have their compounds screened, as appropriate, by the NINDS ETSP Program. Investigators are expected to have an established record of achievement in the area. Full intellectual property (IP) rights (composition of matter) are preferred over method of use IP.
Clinical programs must have a reasonable protocol and sample size to assure that the results will be meaningful; studies of patients should describe the type of seizure/epilepsy that will be investigated. Investigators proposing a clinical trial should include the protocol in the appliation materials. If another entity, such as a pharmaceutical company, is providing partial funding support or in-kind contribution to the study (such as study drug and/or placebo), please provide a letter of support detailing the agreed upon funding or resources provided. Device programs should present novel concepts for treatment. Applicants should apply for the amount needed to complete the project or the project phase to complete the project. Detailed budgets are encouraged.
Confidential information should NOT be sent to the Epilepsy Foundation or provided in any grant application without advance discussion with the Epilepsy Foundation and only with appropriate confidentiality agreements.
Scientific questions about appropriateness of an application should be directed to Brandy Fureman, email@example.com.
Investigators must submit a
Letter of Intent by
July 21, 2017 by 11:59 pm ET.
The deadline for receipt of
full Grant proposals is
September 25, 2017 by 11:59 pm ET.
Full proposals will be accepted
only from Investigators whose
Letter of Intent was approved.